Morgan & Masterson is involved with many projects concerned with the introduction of new biomaterials, medical devices and technologies into health care. This includes not just the development of the materials and technologies but also the analysis of the risk – benefits dynamic and the balance between innovation and risk. This can occur at individual company level, for example through the scientific input into risk management procedures, the development of design history files and the expert construction of failure modes and effects analyses. These are not trivial matters since the protection of patients and the careful introduction of new technologies have to be scientifically driven within the companies themselves. This also occurs at higher levels, for example through trade associations, patient support groups, standards organizations, regulatory agencies and within national and international governmental bodies. Morgan & Masterson engage with all of the types of organizations in the development and analysis of innovative technologies.